「寄付講座 臨床遺伝学研究室」の研究業績のデータです。 [ 論　文 ] 1. Kubota T., Tsukimura T., Shiga T., Togawa T., Sakuraba H.: Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy. CEN Case Reports, 12: 171-175, 2023. doi: 10.1007/s13730-022-00738-7. 2. Nakajima I., Tsukimura T., Ono T., Shiga T., Shitara H., Togawa T., Sakuraba H., Miyaoka Y.: In vivo Delivery of therapeutic molecules by transplantation of genome-edited induced pluripotent stem cells. Cell Transplant, 2023. 32: 9636897231173734. doi: 10.1177/09636897231173734. 3. Shiga T., Tsukimura T., Kubota T., Togawa T., Sakuraba H.: Profiles of globotriaosylsphingosine analogues and globotriaosylceramide isoforms accumulated in body fluids from various phenotypic Fabry patients. Intern Med., DOI: 10.2169/internalmedicine.2493-23, 2023. 4. Shima H., Tsukimura T., Shiga T., Togawa T., Sakuraba H., Doi T., Ikeda Y., Okamoto T., Yoshikawa Y., Kimura T., Iwase T., Inoue T., Tashiro M., Oakada K., Minakuchi J.: Effects of dose increase of enzyme replacement therapy on biomarkers, renal and cardiac parameters, and disease severity in Fabry disease forming neutralizing antidrug antibodies: a case report. CEN Case Rep., doi: 10.1007/s13730-023-00843-1.